Recipharm gets Skr805m in rights issue for growth
Recipharm, the Swedish pharmaceutical company, has completed its Skr805m (€86m) rights issue to finance its acquisition of Kemwell’s manufacturing outsourcing businesses in India, Sweden and the US.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: